Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul>
 <li>Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company at the forefront of developing next-generation Targeted Copper Theranostics (TCTs) for the diagnosis and treatment of cancer.</li>
 <li>The company's proprietary SAR Technology platform, which utilizes the 'perfect pairing' of copper-64 for imaging and copper-67 for therapy, offers significant logistical and potential efficacy advantages over existing radiopharmaceuticals.</li>
 <li>With a diversified pipeline targeting large oncology markets such as prostate and breast cancer, alongside orphan indications like neuroblastoma, Clarity is advancing multiple products through late-stage clinical trials, positioning it for potential commercialization and significant market disruption.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company at the forefront of developing next-generation Targeted Copper Theranostics (TCTs) for the diagnosis and treatment of cancer.
  The company's proprietary SAR Technology platform, which utilizes the 'perfect pairing' of copper-64 for imaging and copper-67 for therapy, offers significant logistical and potential efficacy advantages over existing radiopharmaceuticals.
  With a diversified pipeline targeting large oncology markets such as prostate and breast cancer, alongside orphan indications like neuroblastoma, Clarity is advancing multiple products through late-stage clinical trials, positioning it for potential commercialization and significant market disruption.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Clarity Pharmaceuticals Ltd (CU6 AU) - Aug 2026

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

Clarity Pharmaceuticals Ltd / Index Rebalance

<ul>
<li>In this insight, we take a look at the potential index changes for ASX 200, 100, 50, and 20 in the run-up to the December 2025 index rebal event.</li>
<li>We expect two changes for ASX 50, two changes for ASX 100, and seven changes for ASX 200.</li>
<li>The official index changes will be announced after the close on Friday 5th December 2025.</li>
</ul>


In this insight, we take a look at the potential index changes for ASX 200, 100, 50, and 20 in the run-up to the December 2025 index rebal event.
We expect two changes for ASX 50, two changes for ASX 100, and seven changes for ASX 200.
The official index changes will be announced after the close on Friday 5th December 2025.


Quiddity Leaderboard ASX Dec25: Reference Period Ending Soon; Some Surprises Possible

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Ono Pharmaceutical received FDA approval for Romvimza for the treatment of symptomatic tenosynovial giant cell tumor. Shionogi obtains domestic approval for digital therapeutic app, Endeavorride for ADHD.</li>
<li>Samsung Biologics received FDA and European Commission approval for Prolia biosimilar. Celltrion received European approval for Prolia and Eylea biosimilars. Cosette Pharmaceuticals is acquiring Mayne Pharma for A$7.40 per share.</li>
<li>CSPC Pharmaceutical granted an exclusive license to Radiance Biopharma to develop and commercialize antibody drug conjugates SYS6005 in selected geographies. Cipla received FDA approval for anti-cancer drug Nilotinib capsules.</li>
</ul>


Ono Pharmaceutical received FDA approval for Romvimza for the treatment of symptomatic tenosynovial giant cell tumor. Shionogi obtains domestic approval for digital therapeutic app, Endeavorride for ADHD.
Samsung Biologics received FDA and European Commission approval for Prolia biosimilar. Celltrion received European approval for Prolia and Eylea biosimilars. Cosette Pharmaceuticals is acquiring Mayne Pharma for A$7.40 per share.
CSPC Pharmaceutical granted an exclusive license to Radiance Biopharma to develop and commercialize antibody drug conjugates SYS6005 in selected geographies. Cipla received FDA approval for anti-cancer drug Nilotinib capsules.


APAC Healthcare Weekly (Feb 23)- Ono Pharma, Shionogi, Samsung Biologics, Celltrion, CSPC, Mayne

<ul>
<li>Hansoh Pharmaceutical announced that a new indication of Xinyue has been included in the Priority Review. Astellas Pharma announced positive update from the Phase 3 EV-302 clinical trial.</li>
<li>CSL has received EU approval for HAE drug, Andemry. Imugene announce more positive results from its Phase 1b trial of azer-cel, an allogenic therapy in relapsed/refractory diffuse large B-cell lymphoma.</li>
<li>LigaChem Bio signed technology transfer agreement for a new anticancer target antibody for the development of ADC candidates with Daan Biotherapeutics. Lupin received FDA approval for generic Atrovent Nasal Spray.</li>
</ul>


Hansoh Pharmaceutical announced that a new indication of Xinyue has been included in the Priority Review. Astellas Pharma announced positive update from the Phase 3 EV-302 clinical trial.
CSL has received EU approval for HAE drug, Andemry. Imugene announce more positive results from its Phase 1b trial of azer-cel, an allogenic therapy in relapsed/refractory diffuse large B-cell lymphoma.
LigaChem Bio signed technology transfer agreement for a new anticancer target antibody for the development of ADC candidates with Daan Biotherapeutics. Lupin received FDA approval for generic Atrovent Nasal Spray.


APAC Healthcare Weekly (Feb 16)- Hansoh Pharma, Astellas Pharma, CSL, Imugene, LigaChem Bio, Lupin

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Event-Driven

<ul>
<li>Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 13th July, published on the 17th July.</li>
<li>The largest industry net increase in the past week was A$0.8bn into "Banks"; the largest industry net decrease was A$0.5bn out of "Diversified Metals". Net shorts declined A$0.2bn week-on-week.</li>
<li>Companies mentioned in this regular weekly report include: <a href="https://www.smartkarma.com/entities/pls-group-limited" target="_blank" data-smartkarma-citation="entities:7460:1" rel="noopener">PLS Group (PLS AU)</a>, <a href="https://www.smartkarma.com/entities/lynas-corp-ltd" target="_blank" data-smartkarma-citation="entities:20374:1" rel="noopener">Lynas (LYC AU)</a>, <a href="https://www.smartkarma.com/entities/westpac-banking-corp" target="_blank" data-smartkarma-citation="entities:444:1" rel="noopener">Westpac Banking (WBC AU)</a>, <a href="https://www.smartkarma.com/entities/iluka-resources-ltd" target="_blank" data-smartkarma-citation="entities:10105:1" rel="noopener">Iluka Resources (ILU AU)</a>, and <a href="https://www.smartkarma.com/entities/commonwealth-bank-of-australia" target="_blank" data-smartkarma-citation="entities:14:1" rel="noopener">Commonwealth Bank of Australia (CBA AU)</a>.</li>
</ul>


Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 13th July, published on the 17th July.
The largest industry net increase in the past week was A$0.8bn into "Banks"; the largest industry net decrease was A$0.5bn out of "Diversified Metals". Net shorts declined A$0.2bn week-on-week.
Companies mentioned in this regular weekly report include: PLS Group (PLS AU), Lynas (LYC AU), Westpac Banking (WBC AU), Iluka Resources (ILU AU), and Commonwealth Bank of Australia (CBA AU).


Aussie Shorts [13 July 2026]: PLS, Lynas, Westpac, Iluka Resources, Commonwealth Bank

Australia

Clarity Pharmaceuticals Limited operates as a radio-pharmaceutical company. The Company focuses on the developing targeted therapies for the treatment of cancer and other serious diseases. Clarity Pharmaceuticals serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clarity Pharmaceuticals Ltd (CU6 AU)

Primer: Clarity Pharmaceuticals Ltd (CU6 AU) - Aug 2026

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company at the forefront of developing next-generation Targeted Copper...

αSK Primers

Quiddity Leaderboard ASX Dec25: Reference Period Ending Soon; Some Surprises Possible

We have revised our expectations for ASX 100 (please see discussion point below the insight). These are our final expectations for the December...

Janaghan Jeyakumar, CFA

APAC Healthcare Weekly (Feb 23)- Ono Pharma, Shionogi, Samsung Biologics, Celltrion, CSPC, Mayne

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Tina Banerjee

APAC Healthcare Weekly (Feb 16)- Hansoh Pharma, Astellas Pharma, CSL, Imugene, LigaChem Bio, Lupin

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Tina Banerjee

Aussie Shorts [13 July 2026]: PLS, Lynas, Westpac, Iluka Resources, Commonwealth Bank

The largest industry net increase in the past week was A$0.8bn into "Banks"; the largest industry net decrease was A$0.5bn out of "Diversified...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)